| Literature DB >> 35813106 |
Anna E Meade1, Samantha M Cummins1, Jordyn T Farewell1, Sofia Duque2, Sydney K Mulqueen1, Ashleigh Chuah1, Andrew Y Zhang1.
Abstract
Socioeconomic disparities remain prevalent among those who undergo breast reconstruction. At our institution, patients must meet certain criteria to become eligible for breast reconstruction. The purpose of this study was to determine the impact of socioeconomic factors on breast reconstruction eligibility, enrollment, choice, and completion at our large safety-net institution.Entities:
Year: 2022 PMID: 35813106 PMCID: PMC9257304 DOI: 10.1097/GOX.0000000000004410
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Patient Demographics
| Age, y | 56.1 ± 11.9 |
| Race | |
| Hispanic | 311 (50%) |
| African American | 224 (36%) |
| White | 83 (13%) |
| Asian | 7 (1%) |
| BMI | |
| Normal <25 | 106 (16%) |
| Overweight | 193 (30%) |
| Obese | 278 (43%) |
| Morbidly obese | 73 (11%) |
| Diabetes (type 2) | 174 (27%) |
| HgA1c (mean ± SD) | 6.31 ± 1.4 |
| Smoking status | |
| Never | 449 (70%) |
| Former | 131 (20%) |
| Active | 65 (10%) |
| ASA score | |
| I | 19 (3%) |
| II | 299 (46%) |
| III | 321 (50%) |
| IV | 6 (1%) |
| Medical/surgical history | |
| MI | 12 (1.8%) |
| CABG | 6 (0.9%) |
| Abdominoplasty | 7 (1.1%) |
| Cholecystectomy | 33 (5%) |
| Insurance provider | |
| County Financial Assistance | 246 (38%) |
| Medicaid | 171 (26%) |
| Medicare | 117 (18%) |
| Private | 58 (9%) |
| Unspecified | 58 (9%) |
| Cancer Profile | |
| Type | |
| DCIS | 21% |
| IDC | 61% |
| ILC | 3% |
| Other | 15% |
| Cancer stage | |
| 0 | 24% |
| I | 34% |
| II | 24% |
| III | 15% |
| IV | 3% |
CABG, coronary artery bypass grafting; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MI, myocardial infarction.
Fig. 1.Patients who did not undergo immediate TE placement at time of mastectomy.
Fig. 2.Patients undergoing breast surgery.
Association of Insurance Type with Patient Demographics and Oncologic Treatment
| Patient Characteristics | Private Insurance (n = 58) | Government Insurance (n = 476) |
|
|---|---|---|---|
| Mean Income | |||
| Higher quartiles (Q3/Q4) | 33 (57%) | 237 (49%) |
|
| Race | |||
| Minority | 47 (81%) | 423 (89%) |
|
| White | 11 (19%) | 53 (11%) | |
| BMI | |||
| Obese (>30) | 22 (39%) | 254 (53%) | 0.20 |
| Diabetes | 9 (16%) | 112 (24%) | 0.06 |
| HbA1c | 6.0 ± 1.1 | 6.26 ± 1.4 |
|
| Smoking status | |||
| Yes | 5 (9%) | 108 (23%) |
|
| No | 53(91%) | 368 (77%) | |
| ASA |
| ||
| I + II | 1 (2%) | 18 (4.9%) | |
| II | 33 (58%) | 233 (49%) | |
| III + IV | 23 (40%) | 219 (46%) | |
| IV | 0 (0%) | 2 (0.1%) | |
| Adjunct XRT | 33 (58%) | 301 (63%) | 0.4 |
| Adjunct chemotherapy | 21 (37%) | 158 (33%) | 0.75 |
| Did not see plastics | 24 (42%) | 261 (55%) | 0.13 |
| Mastectomy procedure | |||
| Lumpectomy | 30 (53%) | 216 (45%) | 0.15 |
| Complete mastectomy | 27 (47%) | 260 (55%) | |
XRT, radiotherapy.
Breast Cancer Stage and Reconstructive Procedures Based on SES Factors
| Surgical Characteristics | Q3/Q4 | Q1/Q2 |
| Private Insurance | Government Insurance |
| Racial Minority | White |
|
|---|---|---|---|---|---|---|---|---|---|
| Stage of Cancer | n = 301 | n = 316 | 0.08 | n = 53 | n = 445 | n = 535 | n = 89 | 0.33 | |
| 0 (DCIS/LCIS) | 63 (21%) | 65 (21%) | 11 (21%) | 85 (19%) | 110 (21%) | 17 (19%) | |||
| I | 101 (34%) | 120 (38%) | 20 (38%) | 154 (35%) | 187 (35%) | 33 (37%) | |||
| II | 83 (28%) | 72 (23%) | 17 (32%) | 115 (26%) | 137 (26%) | 27 (30%) | |||
| III | 45 (15%) | 52 (16%) | 4 (7%) | 79 (18%) | 88 (16%) | 9 (11%) | |||
| IV | 9 (2%) | 7 (2%) | 1 (2%) | 12 (2%) | 13 (2%) | 3 (3%) | |||
| Complete Mastectomy | n = 155 | n = 167 | n = 26 | n = 221 | n = 216 | n = 31 | |||
| Immediate TE placement/direct-to-implant | 84 (54%) | 93 (56%) | 0.92 | 18 (69%) | 127 (57%) |
| 129 (60%) | 16 (52%) |
|
| Complications after TE placement/direct-to-implant | 29 (19%) | 31 (18%) | 0.88 | 9 (35%) | 40 (18%) | 0.06 | 42 (19%) | 7 (23%) | 0.06 |
| Definitive breast reconstruction completed |
| 12 (46%) | 87 (39%) | 0.11 | 88 (41%) | 15 (48%) | 0.4 | ||
| Complications after definitive breast reconstruction | 16 (10%) | 10 (6%) | 0.55 | 3 (12%) | 17 (8%) | 0.29 | 17 (8%) | 3 (10%) | 0.73 |
| Definitive breast reconstruction modalities | n = 70 | n = 63 | n = 12 | n = 87 | n = 88 | n = 15 | |||
| Implant-based | 29 (41%) | 20 (32%) | 0.86 | 6 (50%) | 34 (39%) | 0.53 | 41 (47%) | 8 (53%) | 0.59 |
| Autologous | 41 (59%) | 43 (68%) | 6 (50%) | 53 (61%) | 17 (8%) | 7 (47%) | |||
| Secondary revisions | 22 (31%) | 20 (32%) | 0.94 | 3 (25%) | 39 (45%) | 0.13 | 37 (42%) | 5 (33%) | 0.78 |
Bold values indicate statistical significance, as indicated by a p value less than 0.05.
Multivariable Logistic Regression
| Dependent Variables | Demographic and Socioeconomic Factors |
| OR (95% CI for OR) |
|---|---|---|---|
| Receiving plastic surgery consult | Government-based insurance | 0.06 | 0.64 (0.40–1.02) |
| Age | 0.96 | 1.00 (0.99–1.02) | |
| Racial minority | 0.10 | 1.50 (0.92–2.44) | |
| BMI >30 | 0.29 | 0.83 (0.58–1.18) | |
| Type 2 diabetes diagnosis | 0.00 | 0.30 (0.18–0.49) | |
| ASA ≥3 | 0.04 | 0.69 (0.49–0.98) | |
| Q1 | 0.77 | ||
| Q2 | 0.76 | 1.08 (0.66–1.78) | |
| Q3 | 0.90 | 0.97 (0.59–1.59) | |
| Q4 | 0.47 | 0.83 (0.51–1.37) | |
| Adjunct XRT | 0.31 | 0.83 (0.58–1.19) | |
| Adjunct chemotherapy | 0.73 | 1.08 (0.69–1.71) | |
| Active smoker | 0.00 | 0.30 (0.10–0.40) | |
| Immediate TE placement/direct-to-implant breast reconstruction | Government-based insurance | 0.17 | 1.409 (0.863–2.3) |
| Age | 0.477 | 0.994 (0.977–1.011) | |
| Racial minority | 0.302 | 0.757 (0.446–1.285) | |
| BMI >30 | 0.201 | 1.284 (0.875–1.884) | |
| Type 2 diabetes | 0.00 | 5.228 (2.784–9.82) | |
| ASA ≥3 | 0.112 | 1.365 (0.93–2.001) | |
| Q1 | 0.863 | ||
| Q2 | 0.903 | 1.034 (0.605–1.768) | |
| Q3 | 0.994 | 0.998 (90.585–1.702) | |
| Q4 | 0.475 | 1.219 (0.709–2.096) | |
| Adjunct XRT | 0.332 | 1.217 (0.819–1.808) | |
| Adjunct chemotherapy | 0.875 | 0.961 (0.585–1.579) | |
| Active smoker | 0.002 | 0.264 (0.116–0.602) | |
| Final definitive breast reconstruction | Government-based insurance | 0.398 | 1.262 (0.736–2.164) |
| Age | 0.306 | 0.99 (0.972–1.009) | |
| Racial minority | 0.144 | 0.628 (0.337–1.172) | |
| BMI >30 | 0.749 | 1.073 (0.697–1.651) | |
| Type 2 diabetes | 0.00 | 6.019 (2.872–12.613) | |
| ASA ≥3 | 0.523 | 1.151 (0.748–1.771) | |
| Q1 | 0.147 | ||
| Q2 | 0.462 | 0.801 (0.444–1.446) | |
| Q3 | 0.151 | 0.64 (0.348–1.177) | |
| Q4 | 0.46 | 1.246 (0.695–2.232) | |
| Adjunct XRT | 0.399 | 1.211 (0.776–1.89) | |
| Adjunct chemotherapy | 0.276 | 1.352 (0.786–2.326) | |
| Active smoker | 0.004 | 0.172 (0.052–0.564) | |
| Postoperative complications | Government-based insurance | 0.11 | 0.54 (0.26–1.15) |
| Age | 0.64 | 0.99 (0.95–1.03) | |
| Ethnicity | 0.25 | 1.95 (0.63–6.02) | |
| BMI >30 | 0.03 | 5.35 (1.14–25.01) | |
| Type 2 diabetes | 0.98 | ||
| ASA ≥3 | 0.45 | 1.24 (0.72–2.14) | |
| Q1 | 0.61 | ||
| Q2 | 0.40 | 1.39 (0.65–2.98) | |
| Q3 | 0.95 | 1.02 (0.48–2.19) | |
| Q4 | 0.27 | 1.55 (0.71–3.37) | |
| Adjunct XRT | 0.02 | 0.53 (0.30–0.92) | |
| Adjunct chemotherapy | 0.08 | 1.66 (0.94–2.92) | |
| Active smoker | 0.45 | 1.52 (0.52–4.49) |
DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; XRT, radiotherapy.